These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 12380630)

  • 1. Pegylated interferons for the treatment of chronic hepatitis C infection.
    Luxon BA; Grace M; Brassard D; Bordens R
    Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
    Foster GR
    Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
    Rajender Reddy K; Modi MW; Pedder S
    Adv Drug Deliv Rev; 2002 Jun; 54(4):571-86. PubMed ID: 12052715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.
    Lurie Y; Rouzier-Panis R; Webster GJ; Dusheiko GM; Laughlin M; Jackson ML; Oren R
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):610-5. PubMed ID: 15952104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].
    Znoyko OO; Klimova EA; Maevskaya MV; Shuldyakov АA; Linkova YN; Morozova MA
    Ter Arkh; 2016; 88(11):156-162. PubMed ID: 28635836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
    Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa-2a: a review of approved and investigational uses.
    Matthews SJ; McCoy C
    Clin Ther; 2004 Jul; 26(7):991-1025. PubMed ID: 15336466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon monotherapy for chronic hepatitis C.
    Heathcote J; Zeuzem S
    Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
    Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.
    Bosques-Padilla F; Trejo-Estrada R; Campollo-Rivas O; Cortez-Hernández C; Dehesa-Violante M; Maldonado-Garza H; Pérez-Gómez R; Cabrera-Valdespino A
    Ann Hepatol; 2003; 2(3):135-9. PubMed ID: 15115965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.
    Rustgi VK
    Curr Med Res Opin; 2009 Apr; 25(4):991-1002. PubMed ID: 19275518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.